TSE:EPI ESSA Pharma (EPI) Stock Price, News & Analysis → The Next Nvidia? (From InvestorPlace) (Ad) Free EPI Stock Alerts Add Share Share Today's Range N/A50-Day RangeC$0.32▼C$0.3252-Week Range N/AVolume4,700 shsAverage Volume68,239 shsMarket CapitalizationC$9.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ESSA Pharma alerts: Email Address Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About ESSA PharmaESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.Read More Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. EPI Stock News HeadlinesApril 7, 2024 | uk.investing.comESSA Pharma Inc (EPIX)January 30, 2024 | realmoney.thestreet.comEssa Pharma initiated with bullish view at JonesResearch, here's whyApril 23, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.January 26, 2024 | finance.yahoo.comEPIX: Updated Data for Phase 1 Trial of Masofaniten Shows 63% of Patients Achieved PSA <0.2 ng/mL…January 26, 2024 | msn.comWhat's Going On With Prostate Cancer Focused ESSA Pharma Stock Today?January 25, 2024 | finanznachrichten.deESSA Pharma Inc: ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumJanuary 25, 2024 | finance.yahoo.comESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumDecember 12, 2023 | finance.yahoo.comESSA Pharma Inc (EPIX) Reports Fiscal Q4 and Full-Year Earnings, Advances in Prostate Cancer ...April 23, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.November 23, 2023 | finance.yahoo.comDirector Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 SharesNovember 7, 2023 | seekingalpha.comESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC ResistanceOctober 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akero Therapeutics (AKRO) and ESSA Pharma (EPIX)October 6, 2023 | benzinga.comProstate Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)September 20, 2023 | seekingalpha.comESSA Pharma files for $200M mixed shelf offering - filingAugust 9, 2023 | msn.comOppenheimer Reiterates Essa Pharma (EPIX) Outperform RecommendationApril 4, 2023 | msn.comWhy are EpiPens still so expensive?February 13, 2023 | finance.yahoo.comESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)December 19, 2022 | finance.yahoo.comEPIX: Advancing Multiple Clinical Trials in 2023…November 16, 2022 | seekingalpha.comESSA Pharma: EPI-7386+Xtandi Combination Has Shown Highest Efficacy In Metastatic, Castration-Resistant Prostate CancerOctober 31, 2022 | marketwatch.comEssa Pharma Shares Drop 26% After Janssen Suspends Enrollment for TrialsOctober 31, 2022 | seekingalpha.comESSA drops 26% as Johnson & Johnson ends trial enrollment for lead assetOctober 26, 2022 | finance.yahoo.comESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR SymposiumOctober 26, 2022 | marketwatch.comESSA Pharma Surges 152% on Study Results for Lead Drug CandidateOctober 26, 2022 | finance.yahoo.comPromontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR SymposiumOctober 26, 2022 | seekingalpha.comESSA Pharma jumps 91% on Phase 1/2 data for prostate cancer therapyAugust 10, 2022 | finance.yahoo.comEPIX: Multiple Ongoing Studies of EPI-7386…June 28, 2022 | finance.yahoo.comESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate CancerSee More Headlines Receive EPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolTSE:EPI CUSIPN/A CIKN/A Webessapharmaceuticals.com Phone+1-778-3310962FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares29,102,000Free FloatN/AMarket CapC$9.31 million OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesRichard M. Glickman LL.D. (Age 57)Chairman of the Board David Ross Parkinson M.D. (Age 67)President, Chief Executive Officer, Director David Wood (Age 57)Chief Financial Officer Peter VirsikChief Operating Officer, Executive Vice PresidentRaymond L. Andersen (Age 67)Chief Technology Officer, Director Marianne D. Sadar (Age 53)Chief Scientific Officer, Director Frank Perabo (Age 50)Chief Medical Officer Franklin M. Berger (Age 67)Director Scott Requadt J.D.DirectorGary Sollis (Age 61)Director More ExecutivesInsidersPeter VirsikSold 1,718 sharesTotal: C$5,549.14 ($3.23/share)Franklin Milan BergerBought 23,529 shares on 11/21/2023Total: C$134,821.17 ($5.73/share)Franklin Milan BergerBought 16,471 shares on 11/3/2023Total: C$98,661.29 ($5.99/share) EPI Stock Analysis - Frequently Asked Questions Is ESSA Pharma a good dividend stock? ESSA Pharma (TSE:EPI) pays an annual dividend of C$0.22 per share and currently has a dividend yield of 0.00%. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), bluebird bio (BLUE), Gray Television (GTN), Allergan (AGN), Cardiome Pharma (CRME), CEMEX (CX), Groupon (GRPN), Horizon Therapeutics Public (HZNP) and Tandem Diabetes Care (TNDM). How do I buy shares of ESSA Pharma? Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:EPI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
